of somatostatin

PreclinicalSmall molecule

GGeneral Hospital of Shenyang Military Region

of somatostatin is one of 50 small molecule programs targeting Acute Kidney Injury. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Kidney InjuryActive, not recruiting

Liver CirrhosisNot yet recruiting

Acute Kidney InjuryPreclinical

Active, not recruiting

Liver CirrhosisPreclinical

Not yet recruiting

Competition

Competitive Landscape

92 competitors in Acute Kidney Injury

#DrugCompanyPhaseTrials

Glypressin

MMallinckrodt

Approved

2 2

Inomax

MMallinckrodt

Approved

1 3

Giapreza

LLa Jolla Pharmaceutical Company

Phase 3

2 4

Oraverse

LLife Extension Foundation Inc.

Phase 3

1 5

Lamisil

Novartis

Phase 2

1 6

Northera

Lundbeck

Phase 2

1 7

Desferal

Jazz Pharmaceuticals

Phase 2

1 8

Pitressin

AAultman Health Foundation

Phase 2

1 9

Arginine Vasopressin

SStanford University

Phase 3

1 10

Jardiance

Boehringer Ingelheim

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

PreclinicalNot yet recruiting

Liver Cirrhosis

NCT07252401

Clinical

Trials by Indication[1]

Liver Cirrhosis1 trial

Terlipressin vs. Somatostatin in Cirrhotic Patients With Acute Variceal Bleeding and Renal Dysfunction: A Multicenter Randomized Controlled Trial

Not yet recruiting·GGeneral Hospital of Shenyang Military Region·Preclinical·NCT07252401·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for of somatostatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — of somatostatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for of somatostatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — General Hospital of Shenyang Military Region company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: GGeneral Hospital of Shenyang Military Region

of somatostatin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Liver Cirrhosis1 trial

References

Drug Info

Quick Facts

Related News